Cargando…
Development of therapeutic options on type 2 diabetes in years: Glucagon-like peptide-1 receptor agonist’s role intreatment; from the past to future
Diabetes mellitus (DM) is a chronic metabolic disease characterized by hypergly-cemia. Type 2 diabetes (T2DM) accounting for 90% of cases globally. The worldwide prevalence of DM is rising dramatically over the last decades, from 30 million cases in 1985 to 382 million cases in 2013. It’s estimated...
Autores principales: | Dogruel, Hakan, Balci, Mustafa Kemal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715574/ https://www.ncbi.nlm.nih.gov/pubmed/31523380 http://dx.doi.org/10.4239/wjd.v10.i8.446 |
Ejemplares similares
-
Management of diabetic foot ulcers and the challenging points: An endocrine view
por: Doğruel, Hakan, et al.
Publicado: (2022) -
Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndrome
por: Chatterjee, Sanjay, et al.
Publicado: (2016) -
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
por: Sofogianni, Areti, et al.
Publicado: (2020) -
Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes
por: Nomoto, Hiroshi
Publicado: (2023) -
Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
por: Kalra, Sanjay, et al.
Publicado: (2016)